Stay updated with breaking news from Birgit Girshick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. ...
Baillie Gifford & Co. lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 6.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,572 shares of the medical research company’s stock after selling 5,524 shares during the period. […]
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) shares rose 7.3% during mid-day trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $237.16 and last traded at $236.41. Approximately 459,031 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities researchers at Guggenheim from a “buy” rating to a “neutral” rating in a report issued on Thursday, Briefing.com reports. Other analysts have also issued research reports about the stock. Citigroup boosted their price target on shares of Charles River Laboratories International from […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) had its price objective raised by equities researchers at UBS Group from $270.00 to $290.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. UBS Group’s price target would suggest a potential […]